1
|
Waters JP, Horenstein S, Egger A, Johnsen P, Kim TW. Parosteal lipoma of the left femur: A case report. Clin Case Rep 2024; 12:e8744. [PMID: 38654936 PMCID: PMC11035377 DOI: 10.1002/ccr3.8744] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2023] [Accepted: 03/24/2024] [Indexed: 04/26/2024] Open
Abstract
Multidisciplinary team collaboration in the diagnosis of rare tumors such as parosteal lipoma is highly important, especially when suspicious of malignancy. The use of radiological and physical examinations is imperative to monitor recurrence and quality of life.
Collapse
Affiliation(s)
- James P. Waters
- Cooper Medical School of Rowan UniversityCamdenNew JerseyUSA
| | | | - Austin Egger
- Philadelphia College of Osteopathic MedicinePhiladelphiaPennsylvaniaUSA
| | | | - Tae Won Kim
- Cooper University HealthcareCamdenNew JerseyUSA
| |
Collapse
|
2
|
Rubinstein WS, Patriotis C, Dickherber A, Han PKJ, Katki HA, LeeVan E, Pinsky PF, Prorok PC, Skarlupka AL, Temkin SM, Castle PE, Minasian LM. Cancer screening with multicancer detection tests: A translational science review. CA Cancer J Clin 2024. [PMID: 38517462 DOI: 10.3322/caac.21833] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/21/2023] [Revised: 02/06/2024] [Accepted: 02/12/2024] [Indexed: 03/23/2024] Open
Abstract
Multicancer detection (MCD) tests use a single, easily obtainable biospecimen, such as blood, to screen for more than one cancer concurrently. MCD tests can potentially be used to improve early cancer detection, including cancers that currently lack effective screening methods. However, these tests have unknown and unquantified benefits and harms. MCD tests differ from conventional cancer screening tests in that the organ responsible for a positive test is unknown, and a broad diagnostic workup may be necessary to confirm the location and type of underlying cancer. Among two prospective studies involving greater than 16,000 individuals, MCD tests identified those who had some cancers without currently recommended screening tests, including pancreas, ovary, liver, uterus, small intestine, oropharyngeal, bone, thyroid, and hematologic malignancies, at early stages. Reported MCD test sensitivities range from 27% to 95% but differ by organ and are lower for early stage cancers, for which treatment toxicity would be lowest and the potential for cure might be highest. False reassurance from a negative MCD result may reduce screening adherence, risking a loss in proven public health benefits from standard-of-care screening. Prospective clinical trials are needed to address uncertainties about MCD accuracy to detect different cancers in asymptomatic individuals, whether these tests can detect cancer sufficiently early for effective treatment and mortality reduction, the degree to which these tests may contribute to cancer overdiagnosis and overtreatment, whether MCD tests work equally well across all populations, and the appropriate diagnostic evaluation and follow-up for patients with a positive test.
Collapse
Affiliation(s)
- Wendy S Rubinstein
- Division of Cancer Prevention, US National Cancer Institute, Rockville, Maryland, USA
| | - Christos Patriotis
- Division of Cancer Prevention, US National Cancer Institute, Rockville, Maryland, USA
| | - Anthony Dickherber
- Center for Strategic Scientific Initiatives, US National Cancer Institute, Rockville, Maryland, USA
| | - Paul K J Han
- Division of Cancer Control and Population Sciences, US National Cancer Institute, Rockville, Maryland, USA
| | - Hormuzd A Katki
- Division of Cancer Epidemiology and Genetics, US National Cancer Institute, Rockville, Maryland, USA
| | - Elyse LeeVan
- Division of Cancer Prevention, US National Cancer Institute, Rockville, Maryland, USA
| | - Paul F Pinsky
- Division of Cancer Prevention, US National Cancer Institute, Rockville, Maryland, USA
| | - Philip C Prorok
- Division of Cancer Prevention, US National Cancer Institute, Rockville, Maryland, USA
| | - Amanda L Skarlupka
- Division of Cancer Prevention, US National Cancer Institute, Rockville, Maryland, USA
| | - Sarah M Temkin
- National Institutes of Health Office of Research on Women's Health, Bethesda, Maryland, USA
| | - Philip E Castle
- Division of Cancer Prevention, US National Cancer Institute, Rockville, Maryland, USA
- Division of Cancer Epidemiology and Genetics, US National Cancer Institute, Rockville, Maryland, USA
| | - Lori M Minasian
- Division of Cancer Prevention, US National Cancer Institute, Rockville, Maryland, USA
| |
Collapse
|
3
|
Cardani R, Bertoldo EG, Cerri A, Picozzi M, Corsi Romanelli MM, Callus E. Establishment of a cardiac biobank in a Department of Pathology and Laboratory Medicine. J BIOL REG HOMEOS AG 2021; 34:1983-1991. [PMID: 33426856 DOI: 10.23812/20-158-r] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
Biobanks are considered to be important resources of Departments of Pathology and Laboratory Medicine allowing the clarification of relevant disease mechanisms and the improvement of the diagnosis, prognosis, and treatment of both pediatric and adult cardiovascular diseases. To successfully establish a cardiovascular biobank, it is important to consider the public opinion and views on it and the factors involved in the willingness of the public to participate in the donation of genetic material. The literature was systematically reviewed to identify the attitude and willingness of patients affected by congenital and acquired heart disease to participate in biobanking research. Six relevant studies were identified in which it was indicated that psychosocial and demographic characteristics, as well as the patient's medical condition, could influence patient and family members' attitudes and willingness to participate in research. In both congenital and acquired heart diseases, participation in biobank research activities was higher if patients and their families were approached when hospitalized, but not during the acute moment of their illness. Other quantitative and qualitative studies are required to improve patient and family participation in these research initiatives.
Collapse
Affiliation(s)
- R Cardani
- BioCor Biobank, UOC SMEL-1 of Clinical Pathology, IRCCS-Policlinico San Donato, San Donato Milanese, Milan, Italy
| | - E G Bertoldo
- Clinical Psychology Service, IRCCS Policlinico San Donato, San Donato Milanese, Italy
| | - A Cerri
- Scientific Directorate, IRCCS Policlinico San Donato, San Donato Milanese, Italy.,Center for Clinical Ethics (CREC), Insubria University, Varese, Italy
| | - M Picozzi
- Center for Clinical Ethics (CREC), Insubria University, Varese, Italy
| | - M M Corsi Romanelli
- Department of Biomedical Sciences for Health, University of Milan, Milan, Italy.,UOC SMEL-1 of Clinical Pathology, IRCCS Policlinico San Donato, San Donato Milanese, Milan, Italy
| | - E Callus
- Clinical Psychology Service, IRCCS Policlinico San Donato, San Donato Milanese, Italy.,Department of Biomedical Sciences for Health, University of Milan, Milan, Italy
| |
Collapse
|
4
|
Vanuytsel K, Mithal A, Giadone RM, Yeung AK, Matte TM, Dowrey TW, Werder RB, Miller GJ, Miller NS, Andry CD, Murphy GJ. Rapid Implementation of a SARS-CoV-2 Diagnostic Quantitative Real-Time PCR Test with Emergency Use Authorization at a Large Academic Safety Net Hospital. Med 2020; 1:152-157.e3. [PMID: 32838351 PMCID: PMC7235561 DOI: 10.1016/j.medj.2020.05.001] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/09/2020] [Revised: 04/24/2020] [Accepted: 05/01/2020] [Indexed: 01/16/2023]
Abstract
BACKGROUND Significant delays in the rapid development and distribution of diagnostic testing for SARS-CoV-2 (COVID-19) infection have prevented adequate public health management of the disease, impacting the timely mapping of viral spread and the conservation of personal protective equipment. Furthermore, vulnerable populations, such as those served by the Boston Medical Center (BMC), the largest safety net hospital in New England, represent a high-risk group across multiple dimensions, including a higher prevalence of pre-existing conditions and substance use disorders, lower health maintenance, unstable housing, and a propensity for rapid community spread, highlighting the urgent need for expedient and reliable in-house testing. METHODS We developed a SARS-CoV-2 diagnostic medium-throughput qRT-PCR assay with rapid turnaround time and utilized this Clinical Laboratory Improvement Amendments (CLIA)-certified assay for testing nasopharyngeal swab samples from BMC patients, with emergency authorization from the Food and Drug Administration (FDA) and the Massachusetts Department of Public Health. FINDINGS The in-house testing platform displayed robust accuracy and reliability in validation studies and reduced institutional sample turnaround time from 5-7 days to less than 24 h. Of over 1,000 unique patient samples tested, 44.1% were positive for SARS-CoV-2 infection. CONCLUSIONS This work provides a blueprint for academic centers and community hospitals lacking automated laboratory machinery to implement rapid in-house testing. FUNDING This study was supported by funding from the Boston University School of Medicine, the National Institutes of Health, Boston Medical Center, and the Massachusetts Consortium on Pathogen Readiness (MASS CPR).
Collapse
Affiliation(s)
- Kim Vanuytsel
- Center for Regenerative Medicine, Boston University and Boston Medical Center, Boston, MA 02218, USA
- Section of Hematology and Oncology, Department of Medicine, Boston University School of Medicine, Boston, MA 02218, USA
| | - Aditya Mithal
- Center for Regenerative Medicine, Boston University and Boston Medical Center, Boston, MA 02218, USA
| | - Richard M Giadone
- Center for Regenerative Medicine, Boston University and Boston Medical Center, Boston, MA 02218, USA
| | - Anthony K Yeung
- Center for Regenerative Medicine, Boston University and Boston Medical Center, Boston, MA 02218, USA
| | - Taylor M Matte
- Center for Regenerative Medicine, Boston University and Boston Medical Center, Boston, MA 02218, USA
| | - Todd W Dowrey
- Center for Regenerative Medicine, Boston University and Boston Medical Center, Boston, MA 02218, USA
| | - Rhiannon B Werder
- Center for Regenerative Medicine, Boston University and Boston Medical Center, Boston, MA 02218, USA
| | - Gregory J Miller
- Center for Regenerative Medicine, Boston University and Boston Medical Center, Boston, MA 02218, USA
| | - Nancy S Miller
- Department of Pathology and Laboratory Medicine, Boston Medical Center and Boston University School of Medicine, Boston, MA 02218, USA
| | - Christopher D Andry
- Department of Pathology and Laboratory Medicine, Boston Medical Center and Boston University School of Medicine, Boston, MA 02218, USA
| | - George J Murphy
- Center for Regenerative Medicine, Boston University and Boston Medical Center, Boston, MA 02218, USA
- Section of Hematology and Oncology, Department of Medicine, Boston University School of Medicine, Boston, MA 02218, USA
| |
Collapse
|
5
|
Howell LP, Wahl S, Ryan J, Gandour-Edwards R, Green R. Educational and Career Development Outcomes Among Undergraduate Summer Research Interns: A Pipeline for Pathology, Laboratory Medicine, and Biomedical Science. Acad Pathol 2019; 6:2374289519893105. [PMID: 31858021 PMCID: PMC6913060 DOI: 10.1177/2374289519893105] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2019] [Revised: 10/12/2019] [Accepted: 10/19/2019] [Indexed: 11/16/2022] Open
Abstract
Nurturing undergraduate students’ interest in careers in science, technology, engineering, and medicine is important to developing the future health-care workforce. Summer research internships provide experiential learning that is important to sustaining students’ interest in science, technology, engineering, and medicine careers and inspiring higher educational goals. The Edmondson Summer Research Internship is a mentored program for undergraduate students in University of California Davis Health’s Department of Pathology and Laboratory Medicine. To evaluate intern satisfaction, perceptions on the program’s influence on their career development, and higher educational outcomes, 102 former interns from a 15-year period were invited to participate in an online survey. Responses were received by 58 (57%) of 102 respondents. Not all respondents answered every question. Overall satisfaction was very high/high in 55 (95%) of 58. Ninety-three percent (54/58) strongly agreed/agreed that the internship was an important part of their career development. Almost all who applied to career/professional opportunities strongly agree/agreed that they perceived the internship to be advantageous (96%, 46/48). Forty-four percent (25/57) received additional education after completing their undergraduate degree, with 25% (14/57) receiving a doctoral degree. Few reported prior experience with a clinical laboratory (8/48, 17%), pathologist (10/48, 21%), or clinical laboratory scientist (12/48, 25%). Based on their internship experience, 55% (32/58) strongly agree/agreed that they positively considered pathology or laboratory medicine as a career choice. The Edmondson Summer Research Internship is seen as important to higher educational goals and career development, increases exposure to pathology and laboratory medicine, and demonstrates the value of hosting a mentored research program for undergraduates.
Collapse
Affiliation(s)
- Lydia Pleotis Howell
- Department of Pathology and Laboratory Medicine, University of California Davis School of Medicine, Sacramento, CA, USA
| | - Sharon Wahl
- Department of Pathology and Laboratory Medicine, University of California Davis School of Medicine, Sacramento, CA, USA
| | - John Ryan
- Department of Pathology and Laboratory Medicine, University of California Davis School of Medicine, Sacramento, CA, USA
| | - Regina Gandour-Edwards
- Department of Pathology and Laboratory Medicine, University of California Davis School of Medicine, Sacramento, CA, USA
| | - Ralph Green
- Department of Pathology and Laboratory Medicine, University of California Davis School of Medicine, Sacramento, CA, USA
| |
Collapse
|
6
|
Wright JR. Calgary Laboratory Services: A Unique Canadian Model for an Academic Department of Pathology and Laboratory Medicine Succeeding in the Face of Provincial Integration of Public, Private, and Academic Laboratories. Acad Pathol 2015; 2:2374289515619944. [PMID: 28725754 PMCID: PMC5479463 DOI: 10.1177/2374289515619944] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/10/2015] [Accepted: 10/31/2015] [Indexed: 11/26/2022] Open
Abstract
Calgary Laboratory Services provides global hospital and community laboratory services
for Calgary and surrounding areas (population 1.4 million) and global academic support for
the University of Calgary Cumming School of Medicine. It developed rapidly after the
Alberta Provincial Government implemented an austerity program to address rising health
care costs and to address Alberta’s debt and deficit in 1994. Over roughly the next year,
all hospital and community laboratory test funding within the province was put into a
single budget, fee codes for fee-for-service test billing were closed, roughly 40% of the
provincial laboratory budget was cut, and roughly 40% of the pathologists left the
province of Alberta. In Calgary, in the face of these abrupt changes in the laboratory
environment, private laboratories, publicly funded hospital laboratories and the medical
school department precipitously and reluctantly merged in 1996. The origin of Calgary
Laboratory Services was likened to an “unhappy shotgun marriage” by all parties. Although
such a structure could save money by eliminating duplicated services and excess capacity
and could provide excellent city-wide clinical service by increasing standardization, it
was less clear whether it could provide strong academic support for a medical school. Over
the past decade, iterations of the Calgary Laboratory Services model have been implemented
or are being considered in other Canadian jurisdictions. This case study analyzes the
evolution of Calgary Laboratory Services, provides a metric-based review of academic
performance over time, and demonstrates that this model, essentially arising as an
unplanned experiment, has merit within a Canadian health care context.
Collapse
Affiliation(s)
- James R Wright
- Department of Pathology and Laboratory Medicine, University of Calgary Cumming School of Medicine and Calgary Laboratory Services, Calgary, Alberta, Canada.,Department of Paediatrics, University of Calgary Cumming School of Medicine, Calgary, Alberta, Canada
| |
Collapse
|